Pennwalt ANDA suitability
Executive Summary
Firm's petition for pseudoephedrine polisterex controlled release 60 mg caps was denied by FDA. The agency said pseudoephedrine polisterex is not suitable for ANDA submission because it is a "new salt of pseudoephedrine" and therefore considered a "new drug" requiring investigations